GlassScriptPhysician profile
Michael Patrick Kennedy
NPI 1558507749
$2,431.65
in general payments reported to CMS, 2019-2025
27 companies · $27.27 in 2025
The $27.27 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,018 · 2022: $133 · 2023: $123 · 2024: $130 · 2025: $27.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $280.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $504.34 | 2021-2025 | |
| Novo Nordisk INC | $345.10 | 2021-2023 | Wegovy |
| Astellas Pharma US INC | $175.55 | 2021 | |
| Lilly USA, LLC | $140.00 | 2021-2024 | Zepbound |
| Astrazeneca Pharmaceuticals LP | $131.48 | 2021 | |
| Janssen Pharmaceuticals, INC | $130.12 | 2021 | |
| Sunovion Pharmaceuticals INC. | $96.46 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.93 | 2021 | |
| Esperion Therapeutics, INC. | $95.58 | 2021 | |
| Gilead Sciences, INC. | $91.13 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $78.07 | 2021 | |
| Glaxosmithkline, LLC. | $71.59 | 2021 | |
| Merck Sharp & Dohme LLC | $70.76 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.39 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $54.61 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $39.75 | 2021 | |
| Amarin Pharma, INC. | $36.66 | 2021 | |
| Eisai INC. | $32.27 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $29.76 | 2021 | |
| Jazz Pharmaceuticals INC. | $29.72 | 2021 | |
| Cardiovascular Systems INC. | $19.82 | 2022 | |
| Daiichi Sankyo INC. | $19.04 | 2021 | |
| Nestle Healthcare Nutrition INC. | $18.88 | 2021 | |
| Abbott Laboratories | $17.13 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.75 | 2021 | |
| Medtronic, INC. | $13.49 | 2022 | |
| Pfizer INC. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.